CZ309926B6 - Vitamin ointment - Google Patents
Vitamin ointment Download PDFInfo
- Publication number
- CZ309926B6 CZ309926B6 CZ2021-323A CZ2021323A CZ309926B6 CZ 309926 B6 CZ309926 B6 CZ 309926B6 CZ 2021323 A CZ2021323 A CZ 2021323A CZ 309926 B6 CZ309926 B6 CZ 309926B6
- Authority
- CZ
- Czechia
- Prior art keywords
- amount
- weight
- oil
- vitamin
- tocopherol
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 24
- 229940088594 vitamin Drugs 0.000 title claims abstract description 9
- 229930003231 vitamin Natural products 0.000 title claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 9
- 239000011782 vitamin Substances 0.000 title claims abstract description 9
- 150000003722 vitamin derivatives Chemical class 0.000 title claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims abstract description 16
- 229930003799 tocopherol Natural products 0.000 claims abstract description 11
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 11
- 229960001295 tocopherol Drugs 0.000 claims abstract description 11
- 239000011732 tocopherol Substances 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 11
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 10
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003921 oil Substances 0.000 claims abstract description 10
- 235000019198 oils Nutrition 0.000 claims abstract description 10
- 229940108325 retinyl palmitate Drugs 0.000 claims abstract description 8
- 235000019172 retinyl palmitate Nutrition 0.000 claims abstract description 8
- 239000011769 retinyl palmitate Substances 0.000 claims abstract description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 7
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 7
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 7
- 241001135917 Vitellaria paradoxa Species 0.000 claims abstract description 6
- 229940081733 cetearyl alcohol Drugs 0.000 claims abstract description 6
- 229960002350 guaiazulen Drugs 0.000 claims abstract description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019489 Almond oil Nutrition 0.000 claims abstract description 5
- 239000008168 almond oil Substances 0.000 claims abstract description 5
- 235000013871 bee wax Nutrition 0.000 claims abstract description 4
- 239000012166 beeswax Substances 0.000 claims abstract description 4
- 239000003240 coconut oil Substances 0.000 claims abstract description 4
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 10
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 244000021150 Orbignya martiana Species 0.000 claims description 5
- PWQIHFCYTPFUME-UHFFFAOYSA-N s-guaiazulene Natural products CC(C)C1=CC=CC2=CC=C(C)C2=C1 PWQIHFCYTPFUME-UHFFFAOYSA-N 0.000 claims description 5
- 244000060011 Cocos nucifera Species 0.000 claims description 4
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 4
- 244000020551 Helianthus annuus Species 0.000 claims description 4
- 235000017011 Mandorlo dulce Nutrition 0.000 claims description 4
- 244000076313 Mandorlo dulce Species 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 abstract description 7
- 235000018936 Vitellaria paradoxa Nutrition 0.000 abstract description 5
- 206010013786 Dry skin Diseases 0.000 abstract description 4
- 239000010480 babassu oil Substances 0.000 abstract description 4
- 230000037336 dry skin Effects 0.000 abstract description 4
- 230000003628 erosive effect Effects 0.000 abstract description 4
- 229940057910 shea butter Drugs 0.000 abstract description 3
- 235000020238 sunflower seed Nutrition 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 description 8
- 230000006866 deterioration Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000035876 healing Effects 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 4
- 208000007287 cheilitis Diseases 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000005230 Leg Ulcer Diseases 0.000 description 3
- 235000014643 Orbignya martiana Nutrition 0.000 description 3
- 239000003470 adrenal cortex hormone Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 206010000501 Acne conglobata Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 150000001545 azulenes Chemical class 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000006934 radiodermatitis Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Vitaminová mastVitamin ointment
Oblast technikyField of technology
Navrhovaný vynález je vitaminová mast pro podporu epitelizace pokožky. Mast je vhodná k péči o suchou pokožku se sklonem k prasklinám (ragádám), trhlinám (fisurám) a erozivním ekzémům. Napomáhá epitelizaci pokožky.The proposed invention is a vitamin ointment for the support of epithelization of the skin. The ointment is suitable for the care of dry skin prone to cracks, fissures and erosive eczema. Helps epithelize the skin.
Dosavadní stav technikyCurrent state of the art
Při péči o suchou nebo jinak poškozenou pokožku se v současné době využívá lékařská bílá vazelína (vaselinum album). Ta neobsahuje žádné aktivní látky, takže nemá epitelizační schopnosti. Slouží pouze k promazání a působí pouze okluzivním efektem.Medical white vaseline (vaselinum album) is currently used in the care of dry or otherwise damaged skin. It does not contain any active substances, so it has no epithelizing abilities. It is only used for lubrication and has only an occlusive effect.
Dalším známým prostředkem je mast známá pod obchodním názvem Infadolan. Mast obsahuje retinol-acetát a ergokalciferol (vitamin D2) a jako pomocné látky bílý vosk, tuk z ovčí vlny a bílou vazelínu. Mast díky svému složení poskytuje epitelizační efekt, který ale není příliš výrazný.Another well-known remedy is an ointment known under the trade name Infadolan. The ointment contains retinol acetate and ergocalciferol (vitamin D2) and as excipients white wax, fat from sheep's wool and white petroleum jelly. Thanks to its composition, the ointment provides an epithelization effect, but it is not very pronounced.
Úkolem vynálezu tak je poskytnout prostředek (mast), který poskytne silný epitelizační účinek a zlepší stav pokožky u běžných dermatologických diagnóz.The task of the invention is to provide a means (ointment) that provides a strong epithelizing effect and improves the condition of the skin in common dermatological diagnoses.
Podstata vynálezuThe essence of the invention
Podstatou vynálezu je složení vitaminové masti. Mast slouží pro podporu epitelizace pokožky. Mast sestává z bambuckého másla (Butyrospermum Parkii Butter) 25 až 35 % hmotn., kokosového oleje (Cocos Nucifera Oil) 25 až 35 % hmotn., mandlového oleje (Prunus Amygdalus Dulcis Oil) 12 až 18 % hmotn., mastného alkoholu (Cetearyl Alcohol) 8 až 12 % hmotn., oleje babassu (Orbignya Oleifera Seed Oil) 4 až 6 % hmotn., běleného včelího vosku (Cera Alba) 4 až 6 % hmotn., tokoferolu (Tocopherol) - přirozeného vitaminu E 0,8 až 1,2 % hmotn., kalcium panthotenátu (Calcium Pantothenate) 0,15 až 0,25 % hmotn., tokoferol acetátu (Tocopheryl Acetate) - syntetického vitaminu E 0,07 až 0,13 % hmotn., guajazulenu (Guaiazulen) 0,07 až 0,13 % hmotn., retinyl palmitátu (Retinyl Palmitate) - kombinace vitaminu A1 a kyseliny palmitové 0,02 až 0,05 % hmotn. a slunečnicového oleje (Helianthus Annuus Seed Oil) 0,02 až 0,05 % hmotn.The essence of the invention is the composition of vitamin ointment. The ointment is used to support epithelization of the skin. The ointment consists of shea butter (Butyrospermum Parkii Butter) 25 to 35% by weight, coconut oil (Cocos Nucifera Oil) 25 to 35% by weight, almond oil (Prunus Amygdalus Dulcis Oil) 12 to 18% by weight, fatty alcohol (Cetearyl Alcohol) 8 to 12% by weight, babassu oil (Orbignya Oleifera Seed Oil) 4 to 6% by weight, bleached beeswax (Cera Alba) 4 to 6% by weight, tocopherol (Tocopherol) - natural vitamin E 0.8 to 1.2% by weight, calcium pantothenate 0.15 to 0.25% by weight, tocopheryl acetate - synthetic vitamin E 0.07 to 0.13% by weight, guaiazulen 0 .07 to 0.13% by weight, retinyl palmitate (Retinyl Palmitate) - a combination of vitamin A1 and palmitic acid 0.02 to 0.05% by weight. and sunflower oil (Helianthus Annuus Seed Oil) 0.02 to 0.05 wt.%
Retinyl palmitát je stabilizovaný vitamin A, ester retinolu (vitamin A) a kyseliny palmitové, nasycené mastné kyseliny, která je hlavní součástí palmového oleje. Má epitelizační účinek a urychluje granulaci. Příznivě působí na suchou kůži u chronické dermatitidy (zvláště atopické), na popáleniny, eroze, ragády, u ichthyosis vulgaris, pityriasis rubra pilaris, Morbus Darier. Dále je vhodný na nehojící se rány s nedostatečnou epitelizací, jako jsou píštěle, bércové vředy a dekubity. Oproti retinolu je stabilnější a netoxická, rozkládá se enzymaticky až v těle.Retinyl palmitate is a stabilized vitamin A, an ester of retinol (vitamin A) and palmitic acid, a saturated fatty acid that is the main component of palm oil. It has an epithelializing effect and accelerates granulation. It has a beneficial effect on dry skin in chronic dermatitis (especially atopic), burns, erosions, rashes, ichthyosis vulgaris, pityriasis rubra pilaris, Morbus Darier. It is also suitable for non-healing wounds with insufficient epithelization, such as fistulas, leg ulcers and pressure ulcers. Compared to retinol, it is more stable and non-toxic, it breaks down enzymatically in the body.
Tokoferol acetát (vitamin E) má výrazné antioxidační účinky. Příznivě působí při lokální terapii trofických a bércových vředů, sclerodermia circumscripta, lichen sclerosus et athrophicus, lichen planus, balanitis obliterans, craurosis vulvae, induratio penis plastica a xerotica obliterans.Tocopherol acetate (vitamin E) has significant antioxidant effects. It has a beneficial effect in the local therapy of trophic and leg ulcers, sclerodermia circumscripta, lichen sclerosus et athrophicus, lichen planus, balanitis obliterans, craurosis vulvae, induratio penis plastica and xerotica obliterans.
Kombinace tokoferolu (přirozeného vitaminu E) a tokoferol acetátu (syntetického vitaminu E) zajišťuje vysokou míru antioxidačních účinků. Tokoferol ochraňuje vlastní mast a zpomaluje její znehodnocení v čase před aplikací na pokožku. Tokoferol acetát jeThe combination of tocopherol (natural vitamin E) and tocopherol acetate (synthetic vitamin E) ensures a high level of antioxidant effects. Tocopherol protects the ointment itself and slows its deterioration in time before application to the skin. Tocopherol acetate is
- 1 CZ 309926 B6 stabilizovaná forma vitaminu E, která nemá stabilizační účinky ve hmotě (v masti jako takové). Účinkuje po enzymatickém rozkladu v pokožce. Výhoda tokoferol acetátu je, že vykazuje dlouhodobou stabilitu ve hmotě a antioxidační účinek se projeví až v pokožce.- 1 CZ 309926 B6 stabilized form of vitamin E, which does not have stabilizing effects in the substance (in the ointment as such). It works after enzymatic decomposition in the skin. The advantage of tocopherol acetate is that it shows long-term stability in the mass, and the antioxidant effect is only manifested in the skin.
Guajazulen je směs alkylovaných azulenů. Guajazulen působí slabě protisvědivě, adstringentně, protizánětlivě a bakteriostaticky. Podporuje granulaci a epitelizaci.Guajazulene is a mixture of alkylated azulenes. Guajazulen has a weak antipruritic, astringent, anti-inflammatory and bacteriostatic effect. It supports granulation and epithelialization.
Kalcium panthotenát je kalciová sůl ve vodě rozpustného vitaminu B5. Má granulační a epitelizační účinek. Příznivě působí na hojení popálenin, fisur a ragád i bércových vředů, dekubitů a postradiačních dermatitid, včetně rentgenového vředu.Calcium pantothenate is the calcium salt of water-soluble vitamin B5. It has a granulating and epithelizing effect. It has a beneficial effect on the healing of burns, fissures and ragades as well as leg ulcers, pressure ulcers and post-radiation dermatitis, including X-ray ulcers.
Olej babassu (Orbignya Oleifera Seed Oil) pokožku hydratuje a tím zabraňuje jejímu vysychání. Obsahuje kyselinu laurovou, která má antimikrobiální a protizánětlivé účinky. Dále olej obsahuje antioxidanty podobné tokoferolu, které působí na pokožku protektivně.Babassu oil (Orbignya Oleifera Seed Oil) hydrates the skin and thus prevents it from drying out. It contains lauric acid, which has antimicrobial and anti-inflammatory effects. Furthermore, the oil contains antioxidants similar to tocopherol, which have a protective effect on the skin.
Uvedená kombinace složek tvoří vitaminovou mast, které je zvláště vhodná k péči o suchou pokožku se sklonem k prasklinám (ragádám), trhlinám (fisurám) a erozivním ekzémům. Mast napomáhá epitelizaci pokožky. Je velmi jemná a neobsahuje parabeny ani lanolín a je bez přidaných barviv a parfémů. Díky to mu ji lze aplikovat i na rty a lze ji použít již od novorozeneckého věku.The mentioned combination of ingredients forms a vitamin ointment, which is particularly suitable for the care of dry skin prone to cracks (ragadas), cracks (fissures) and erosive eczema. The ointment helps epithelize the skin. It is very gentle and does not contain parabens or lanolin and is free of added dyes and perfumes. Thanks to this, it can also be applied to his lips and can be used from newborn age.
Testy ukázaly, že při nanesení tenké vrstvy masti na postiženou plochu 2 až 5x denně dochází ve většině případů ke znatelnému urychlení zhojení pokožky. Synergický efekt použitých složek v daném poměru zajišťuje rychlejší hojení i při porovnání s doposud známými přípravky.Tests have shown that when a thin layer of ointment is applied to the affected area 2 to 5 times a day, the healing of the skin is noticeably accelerated in most cases. The synergistic effect of the components used in the given ratio ensures faster healing, even when compared to previously known preparations.
Příklad uskutečnění vynálezuAn example of the implementation of the invention
Vitaminová mast pro podporu epitelizace pokožky v konkrétním provedení sestává z:Vitamin ointment for the support of epithelization of the skin in a specific embodiment consists of:
bambuckého másla (Butyrospermum Parkii Butter) 31,8 % hmotn., kokosového oleje (Cocos Nucifera Oil) 31,8 % hmotn., madlového oleje (Prunus Amygdalus Dulcis Oil) 14,878 % hmotn., cetearyl alkoholu (Cetearyl Alcohol) 10 % hmotn., oleje babassu (Orbignya Oleifera Seed Oil) 5 % hmotn., běleného včelího vosku (Cera Alba) 5 % hmotn., tokoferolu (Tocopherol) 1,05 % hmotn., kalcium panthotenátu (Calcium Pantothenate) 0,204 % hmotn., tokoferol acetátu (Tocopheryl Acetate) 0,102 % hmotn., guajazulenu (Guaiazulen) 0,1 % hmotn., retinyl palmitátu (Retinyl Palmitate) 0,036 % hmotn., slunečnicového oleje (Helianthus Annuus Seed Oil) 0,03 % hmotn.shea butter (Butyrospermum Parkii Butter) 31.8% by weight, coconut oil (Cocos Nucifera Oil) 31.8% by weight, almond oil (Prunus Amygdalus Dulcis Oil) 14.878% by weight, cetearyl alcohol (Cetearyl Alcohol) 10% by weight ., babassu oil (Orbignya Oleifera Seed Oil) 5% by weight, bleached beeswax (Cera Alba) 5% by weight, tocopherol (Tocopherol) 1.05% by weight, calcium pantothenate (Calcium Pantothenate) 0.204% by weight, tocopherol acetate (Tocopheryl Acetate) 0.102% by weight, guaiazulen (Guaiazulen) 0.1% by weight, retinyl palmitate (Retinyl Palmitate) 0.036% by weight, sunflower oil (Helianthus Annuus Seed Oil) 0.03% by weight.
Uvedené složky v tomto konkrétním zastoupení vykazují největší přínos k hojení poškozené pokožky a péči o suchou poškozenou pokožku. S tímto složením byly provedeny testy biologické účinnosti v klinické praxi u čtyř častých dermatologických diagnóz - atopického ekzému, lupénky, mikrobiálního ekzému a zánětu retní červeně. Sběr klinických dat byl prováděn v ambulancích odborného kožního lékaře a bylo hodnoceno celkem 246 pacientů.The mentioned components in this particular representation show the greatest contribution to the healing of damaged skin and the care of dry damaged skin. With this composition, tests of biological effectiveness were carried out in clinical practice for four frequent dermatological diagnoses - atopic eczema, psoriasis, microbial eczema and red lip inflammation. The collection of clinical data was carried out in the clinics of a specialist dermatologist and a total of 246 patients were evaluated.
Vliv používání masti byl ve studii sledován pomocí tří kritérií hodnocených ošetřujícím lékařem a jednoho kritéria hodnoceného pacientem. Lékař hodnotil změnu zánětu (resp. zarudnutí), suchost a integritu pokožky (tedy vliv na epitelizaci pokožky). Pacient hodnotil subjektivní svědění (pruritus). Po stanovení diagnózy a souhlasu pacienta, či jehoThe effect of using the ointment was monitored in the study using three criteria assessed by the attending physician and one criterion assessed by the patient. The doctor evaluated the change in inflammation (or redness), dryness and integrity of the skin (i.e. the effect on epithelization of the skin). The patient assessed subjective itching (pruritus). After establishing the diagnosis and consent of the patient or him
- 2 CZ 309926 B6 zákonného zástupce, obdržel pacient vzorek masti a byl instruován o aplikaci. Způsob aplikace byl lékařem všem pacientům ukázán přímo v ordinaci na jejich kůži tak, aby aplikace byla u všech pacientů totožná. Pacient aplikoval mast na určená místa 2x denně v režimu ráno a večer po hygieně.- 2 CZ 309926 B6 legal representative, the patient received a sample of the ointment and was instructed on the application. The method of application was shown by the doctor to all patients directly in the doctor's office on their skin so that the application was identical for all patients. The patient applied the ointment to the designated areas twice a day in the morning and evening after hygiene.
Ve skupině atopického ekzému došlo z celkového počtu 106 pacientů k výraznému zlepšení klinického obrazu u 95 pacientů. U 9 pacientů nedošlo k žádné změně po týdnu a u 2 pacientů došlo ke zhoršení stavu a muselo být aplikováno lokální kortikoidní extemum (tab. 1).In the atopic eczema group, out of a total of 106 patients, there was a significant improvement in the clinical picture in 95 patients. In 9 patients there was no change after a week and in 2 patients the condition worsened and local corticoid extemum had to be applied (Table 1).
Ve skupině lupénky (Psoriasis vulgaris) došlo z celkového počtu 46 pacientů ke zlepšení u 33 z nich. Beze změny se aplikace projevila u 10 pacientů a u 3 došlo ke zhoršení a muselo být nasazeno extemum obsahující calcipotriol a kortikoid. U jednoho zhoršeného pacienta se později prokázalo onemocnění Co vid 19 (tab. 2).In the group of psoriasis (Psoriasis vulgaris), there was improvement in 33 of the total number of 46 patients. The application showed no change in 10 patients and in 3 there was a deterioration and an extemum containing calcipotriol and a corticoid had to be used. One deteriorated patient was later diagnosed with Co vid 19 (Table 2).
Ve skupině mikrobiálního ekzému došlo z celkového počtu hodnocených 45 pacientů ke zlepšení u 39 z nich. U 4 pacientů nedošlo k žádné změně a u 2 pacientů došlo ke zhoršení a muselo být nasazeno kortikoidní extemum (tab. 3).In the microbial eczema group, out of the total number of 45 patients evaluated, 39 of them improved. In 4 patients there was no change and in 2 patients there was a deterioration and corticoid extemum had to be used (Table 3).
-3 CZ 309926 B6-3 CZ 309926 B6
Ve skupině se zánětem retní červeně (Cheilitis sicca) bylo celkem 49 pacientů, z nichž se ve 30 případech jednalo o cheilitídu v rámci léčby celkovými retinoidy pro základné onemocnění Acné conglobata. U všech 49 pacientů došlo k výraznému zlepšení stavu rtů a prakticky vyléčení ložisek. Žádný pacient nezaznamenal setrvalý stav či zhoršení (tab. 4).In the group with red lip inflammation (Cheilitis sicca), there were a total of 49 patients, of which 30 cases involved cheilitis as part of treatment with total retinoids for the underlying disease of Acne conglobata. In all 49 patients, there was a significant improvement in the condition of the lips and practically healing of the deposits. No patient experienced a persistent condition or deterioration (Table 4).
Z celkového počtu 246 pacientů zařazených do studie došlo k signifikantnímu zlepšení klinického stavu u 216 z nich, což představuje 88 %. Předkládaná vitaminová mast ίο prokázala v klinické studii výborný účinek a potvrdila deklarovanou biologickou účinnost.Of the total number of 246 patients included in the study, there was a significant improvement in the clinical condition of 216 of them, which represents 88%. The presented vitamin ointment ίο demonstrated an excellent effect in a clinical study and confirmed the declared biological effectiveness.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2021-323A CZ309926B6 (en) | 2021-07-01 | 2021-07-01 | Vitamin ointment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2021-323A CZ309926B6 (en) | 2021-07-01 | 2021-07-01 | Vitamin ointment |
Publications (2)
Publication Number | Publication Date |
---|---|
CZ2021323A3 CZ2021323A3 (en) | 2023-01-11 |
CZ309926B6 true CZ309926B6 (en) | 2024-02-07 |
Family
ID=84784932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CZ2021-323A CZ309926B6 (en) | 2021-07-01 | 2021-07-01 | Vitamin ointment |
Country Status (1)
Country | Link |
---|---|
CZ (1) | CZ309926B6 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010001665A1 (en) * | 1999-02-11 | 2001-05-24 | Marie Harbeck | Cream compositions for skin management |
WO2018197668A1 (en) * | 2017-04-28 | 2018-11-01 | Isn Pharma Sp.Z.O.O. | Skin care composition |
US20190216871A1 (en) * | 2018-01-17 | 2019-07-18 | KBR Incorporated | Diabetic foot cream |
US20200375887A1 (en) * | 2019-05-27 | 2020-12-03 | Codex Beauty Corporation | Compositions and methods for treating skin |
-
2021
- 2021-07-01 CZ CZ2021-323A patent/CZ309926B6/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010001665A1 (en) * | 1999-02-11 | 2001-05-24 | Marie Harbeck | Cream compositions for skin management |
WO2018197668A1 (en) * | 2017-04-28 | 2018-11-01 | Isn Pharma Sp.Z.O.O. | Skin care composition |
US20190216871A1 (en) * | 2018-01-17 | 2019-07-18 | KBR Incorporated | Diabetic foot cream |
US20200375887A1 (en) * | 2019-05-27 | 2020-12-03 | Codex Beauty Corporation | Compositions and methods for treating skin |
Non-Patent Citations (2)
Title |
---|
MITSUTAKE, Hery, et al. Evaluation of miscibility and polymorphism of synthetic and natural lipids for nanostructured lipid carrier (NLC) formulations by Raman mapping and multivariate curve resolution (MCR). European Journal of Pharmaceutical Sciences, 2019, 135: 51-59; ISSN: 0928-0987 * |
RABASCO ÁLVAREZ, Antonio María; GONZÁLEZ RODRÍGUEZ, María Luisa. Lipids in pharmaceutical and cosmetic preparations. Grasas y Aceites, 51 (1-2), 74-96., 2000; https://idus.us.es/handle/11441/32724 * |
Also Published As
Publication number | Publication date |
---|---|
CZ2021323A3 (en) | 2023-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6528040B1 (en) | EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic | |
US6110908A (en) | Fast acting and persistent topical antiseptic | |
Ishak et al. | Topical application of omega-3-, omega-6-, and omega-9-rich oil emulsions for cutaneous wound healing in rats | |
US8568795B2 (en) | Stabilized formulation comprising omega-3 fatty acids for skin care and/or wound care | |
KR101018352B1 (en) | Composition of comprising bee-venoms for treating acne | |
UA81408C2 (en) | Topical pharmaceutical composition and use thereof for the preparation of medicament for treatment of dermatitis and mucosae inflammatory conditions | |
US10463699B2 (en) | Fish oil topical composition | |
US7074832B2 (en) | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use | |
US8133516B2 (en) | Therapeutic ultrasound gel | |
JP2024059876A (en) | Topical composition composed of cod liver oil for treating wounds and skin disorders | |
US20030064084A1 (en) | Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use | |
Visscher et al. | Vernix caseosa: Formation and functions | |
Karimqulovich | The effect of sertoderm cream in the treatment of moderate and severe forms of acne vulgaris | |
CZ309926B6 (en) | Vitamin ointment | |
US12076303B2 (en) | N-bromotaurine solutions and emulsions against abnormal cells | |
RU2412719C2 (en) | Anti-eczema medication "pro-xylane" | |
US20160367605A1 (en) | Healing composition and use thereof | |
CA3065893A1 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
US20040214891A1 (en) | Method for inhibiting pathogenic bacteria and fungi growth and microbicidal composition | |
BRPI0715182B1 (en) | USE OF A COMPOUND | |
ITMI20132157A1 (en) | CORTEXOLONE 17ALFA-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND / OR ATROPHIC SKIN DISORDERS. 17ALFA CORTEXOLONE-PROPIONED FOR USE IN THE TREATMENT OF SKIN WOUNDS AND / OR ATROPHIC SKIN DISORDERS. | |
KR102561482B1 (en) | Composition for preventing hair loss and improving hair growth and product comprising thereof | |
Saretzky | Second degree burn treated with Curefini ointment and PVC film: an accessible wound care strategy in developing countries | |
JP2014144929A (en) | Composition containing vitamins for preventing or treating acne | |
Hoeger | Neonatal Skin Care |